Long-term management of recurrent uveitis associated with autoimmune lymphoproliferative syndrome.

IF 2.3 Q1 OPHTHALMOLOGY
Timothy Kaftan, Nam V Nguyen, Jack Begley, Helen Song, Brent Timperley, Eric Suhler, Thomas Hejkal, H Nida Sen, Marcus Snow, Steven Yeh
{"title":"Long-term management of recurrent uveitis associated with autoimmune lymphoproliferative syndrome.","authors":"Timothy Kaftan, Nam V Nguyen, Jack Begley, Helen Song, Brent Timperley, Eric Suhler, Thomas Hejkal, H Nida Sen, Marcus Snow, Steven Yeh","doi":"10.1186/s12348-025-00530-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The purpose of this case report is to describe the long-term findings and management of recurrent uveitis in a patient with autoimmune lymphoproliferative syndrome (ALPS).</p><p><strong>Case observation: </strong>A 25-year-old female with a history of ALPS and previous uveitis flares presented with reduced vision and pain in the left eye. Uveitis flares began at age 4 and continued into adulthood prompting multiple medical regimen changes. Ocular involvement included anterior uveitis, posterior uveitis, and panuveitis. The laterality of uveitis flares favored the left eye, however bilateral episodes were documented. The patient was diagnosed with recurrent anterior uveitis and treated with topical corticosteroids with subsequent resolution of her symptoms. However, the patient continued to develop recurrent uveitis prompting low-dose long-term maintenance treatment with topical corticosteroids. Additionally, methotrexate was added which led to uveitis resolution and inactive disease for over a year on this treatment regimen.</p><p><strong>Conclusions: </strong>Uveitis secondary to chronic autoimmune disease, such as ALPS, offer long-term challenges for ocular health management. Due to the recurrent nature of uveitis flares in patients with ALPS, long-term ophthalmic and systemic management may be warranted with low-dose maintenance topical corticosteroid or systemic immunomodulation. Response to topical and systemic therapy can be highly patient specific. Complex side effect profiles of many systemic immunotherapies make drug tolerability an important treatment consideration. Multidisciplinary coordination of systemic immunosuppression should be tailored to the patient's anti-inflammatory needs, as well as careful monitoring of adverse events.</p>","PeriodicalId":16600,"journal":{"name":"Journal of Ophthalmic Inflammation and Infection","volume":"15 1","pages":"67"},"PeriodicalIF":2.3000,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12460203/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Ophthalmic Inflammation and Infection","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s12348-025-00530-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The purpose of this case report is to describe the long-term findings and management of recurrent uveitis in a patient with autoimmune lymphoproliferative syndrome (ALPS).

Case observation: A 25-year-old female with a history of ALPS and previous uveitis flares presented with reduced vision and pain in the left eye. Uveitis flares began at age 4 and continued into adulthood prompting multiple medical regimen changes. Ocular involvement included anterior uveitis, posterior uveitis, and panuveitis. The laterality of uveitis flares favored the left eye, however bilateral episodes were documented. The patient was diagnosed with recurrent anterior uveitis and treated with topical corticosteroids with subsequent resolution of her symptoms. However, the patient continued to develop recurrent uveitis prompting low-dose long-term maintenance treatment with topical corticosteroids. Additionally, methotrexate was added which led to uveitis resolution and inactive disease for over a year on this treatment regimen.

Conclusions: Uveitis secondary to chronic autoimmune disease, such as ALPS, offer long-term challenges for ocular health management. Due to the recurrent nature of uveitis flares in patients with ALPS, long-term ophthalmic and systemic management may be warranted with low-dose maintenance topical corticosteroid or systemic immunomodulation. Response to topical and systemic therapy can be highly patient specific. Complex side effect profiles of many systemic immunotherapies make drug tolerability an important treatment consideration. Multidisciplinary coordination of systemic immunosuppression should be tailored to the patient's anti-inflammatory needs, as well as careful monitoring of adverse events.

自身免疫性淋巴细胞增生性综合征伴复发性葡萄膜炎的长期治疗
背景:本病例报告的目的是描述自身免疫性淋巴细胞增生性综合征(ALPS)患者复发性葡萄膜炎的长期表现和治疗。病例观察:25岁女性,有ALPS病史,既往有葡萄膜炎,左眼视力下降,疼痛。葡萄膜炎始于4岁,一直持续到成年,促使多次改变医疗方案。眼部受累包括前葡萄膜炎、后葡萄膜炎和全葡萄膜炎。葡萄膜炎多发于左眼,但有双侧发作的记录。患者被诊断为复发性前葡萄膜炎,并接受局部皮质类固醇治疗,随后症状得到缓解。然而,患者继续发生复发性葡萄膜炎,促使局部使用皮质类固醇进行低剂量长期维持治疗。此外,加入甲氨蝶呤导致葡萄膜炎消退和非活动性疾病超过一年的治疗方案。结论:继发于慢性自身免疫性疾病(如ALPS)的葡萄膜炎对眼部健康管理提出了长期挑战。由于阿尔卑斯山患者的葡萄膜炎复发性,长期的眼科和全身治疗可能需要低剂量的维持性局部皮质类固醇或全身免疫调节。局部和全身治疗的反应可能是高度患者特异性的。许多全身免疫疗法的复杂副作用概况使得药物耐受性成为重要的治疗考虑因素。系统性免疫抑制的多学科协调应根据患者的抗炎需求量身定制,并仔细监测不良事件。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.80
自引率
3.40%
发文量
39
审稿时长
13 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信